Advertisement
Australia markets close in 5 hours 1 minute

  • ALL ORDS

    7,973.30
    +35.40 (+0.45%)
     

  • ASX 200

    7,718.30
    +34.80 (+0.45%)
     

  • AUD/USD

    0.6495
    +0.0006 (+0.09%)
     

  • OIL

    83.45
    +0.09 (+0.11%)
     

  • GOLD

    2,332.30
    -9.80 (-0.42%)
     

  • Bitcoin AUD

    102,834.10
    -410.74 (-0.40%)
     

  • CMC Crypto 200

    1,435.69
    +20.93 (+1.48%)
     

  • AUD/EUR

    0.6062
    +0.0005 (+0.09%)
     

  • AUD/NZD

    1.0927
    -0.0004 (-0.03%)
     

  • NZX 50

    11,850.17
    +46.89 (+0.40%)
     

  • NASDAQ

    17,471.47
    +260.59 (+1.51%)
     

  • FTSE

    8,044.81
    +20.94 (+0.26%)
     

  • Dow Jones

    38,503.69
    +263.71 (+0.69%)
     

  • DAX

    18,137.65
    +276.85 (+1.55%)
     

  • Hang Seng

    16,828.93
    +317.24 (+1.92%)
     

  • NIKKEI 225

    38,305.60
    +753.44 (+2.01%)
     

Medtronic (MDT) Q3 Earnings Tops, Revenues Miss Estimates

Zacks Equity Research

Are you a medical practitioner? Yes, then you must be aware of Minnesota-based one of the world’s leading medical technology giant Medtronic plc MDT  which has a global reach that extends to roughly 160 countries.

Currently, Medtronic has a Zacks Rank #3 (Hold) but that could change following its third-quarter fiscal 2018 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here). We have highlighted some of the key details from the just-released announcement below:

Earnings: The current Zacks Consensus Estimate stands at $1.24 per share. Medtronic’s adjusted earnings per share of $1.29 exceeded this estimate by 4%.

Revenues: Medtronic posted revenues of $7.55 billion, missing the Zacks Consensus Estimate for revenues of $7.56 billion.

ADVERTISEMENT

Medtronic PLC Price and EPS Surprise

Medtronic PLC Price and EPS Surprise | Medtronic PLC Quote

 

Key Stats: Revenues from Medtronic’s Cardiac and Vascular Group rose 1.6% at constant exchange rate (CER) to $2.79 billion, revenues from Minimally Invasive Therapies Group increased 6.6% at CER to $2.12 billion. Also, revenues from Restorative Therapies Group rose 5.5% at CER to $2.03 billion, while revenues from Diabetes Group rose 6.5% at CER to $610 million.

Major Factors: Per management, third quarter performance was encouraging. Moreover,  strength in the Minimally Invasive Therapies and Restorative Therapies Groups along with solid performance across emerging markets aided in offsetting several market-specific headwinds faced by the company during the reported quarter.

Stock Price: Following the earnings release, share prices rose by a 0.47% in the pre-market trading session till now.

Is Your Investment Advisor Fumbling Your Financial Future?

See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.”

Click to get it free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Medtronic PLC (MDT) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.